Clinical Exome Sequencing Identifies, Two Homozygous LOXHD1 Variants in Two Inbred Families With Pre‐Lingual Hearing Loss From South India
Annals of Human Genetics · 2025
DOI: 10.1111/ahg.12593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Human Genetics, 2025. Verfasst von Mathuravalli Krishnamoorthy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Post Graduate Institute of Basic Medical Sciences, University of Madras (Taramani Campus), Chennai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Hearing Loss. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: DST WOS-A, UGC Research Scientist Scheme, Ad Hoc Research Project.
Abstract (Originalsprache)
In recent years, numerous genetic variants have been linked with prelingual hearing loss (HL). Variants in the LOXHD1 gene (lipoxygenase homology domain—1) associated with DFNB 77 are highly heterogeneous, with different auditory characteristics varying from stable to progressive and mild to profound. To date, 168 DFNB 77 cases have been recorded worldwide. Forty‐one hearing‐impaired (HI) probands, who were previously excluded for a set of four common deafness‐causing genes (viz. , GJB2, GJB6, SLC26A4 , and CDH23) from 33 HI families, were subjected to clinical exome sequencing (CES) involving 285 genes associated with HL. This was followed by a segregation analysis of the available members in the family. We identified two pathogenic LOXHD1 variants in two unrelated inbred families. One is a novel homozygous pathogenic nonsense variant (c.3999C > A; p.C1333X), whereas the other is a likely pathogenic missense variant (c.6046G > T; p.E2046K). In silico tools such as SIFT, PolyPhen‐2, Mutation Taster, CADD, and REVEL scores were used to predict variant pathogenicity. Furthermore, American College of Medical Genetics and Genomics guidelines specific to HL were applied to finally classify a variant as pathogenic or otherwise. The frequency of LOXHD1 variants identified in our study is 4.88% (2/41). This is the first LOXHD1 report associated with non‐syndromic HL in South Indian families.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics, Post Graduate Institute of Basic Medical Sciences, University of Madras (Taramani Campus), Chennai, Tamil Nadu, India.
- The Gordon Institute of TAFE Geelong, Geelong, Victoria, Australia.
- Meenakshi Academy of Higher Education and Research (MAHER), Chennai, Tamil Nadu, India.
- Consultant ENT Surgeon, Madras ENT Research Foundation (MERF) Pvt Ltd, Chennai, Tamil Nadu, India.
ORCID-Profile: Mathuravalli Krishnamoorthy, Chandru Jayasankaran, Jeffrey Justin Margret, Paridhy Vanniya Subramanyam, C R Srikumari Srisailapathy
Förderung
- DST WOS-A
- UGC Research Scientist Scheme
- Ad Hoc Research Project
Zitieren
APA
Krishnamoorthy, M., Jayasankaran, C., Lakshmi, S., Sarvani, C., Margret, J. J., Mahalingam, S., Amritkumar, P., Subramanyam, P. V., S, S. R., & Srisailapathy, C. R. S. (2025). Clinical Exome Sequencing Identifies, Two Homozygous LOXHD1 Variants in Two Inbred Families With Pre‐Lingual Hearing Loss From South India. Annals of Human Genetics. https://doi.org/10.1111/ahg.12593
Vancouver
Krishnamoorthy M, Jayasankaran C, Lakshmi S, Sarvani C, Margret JJ, Mahalingam S, et al. Clinical Exome Sequencing Identifies, Two Homozygous LOXHD1 Variants in Two Inbred Families With Pre‐Lingual Hearing Loss From South India. Annals of Human Genetics. 2025. doi:10.1111/ahg.12593
BibTeX
@article{Krishnamoorthy2025,
author = {Krishnamoorthy, Mathuravalli and Jayasankaran, Chandru and Lakshmi, Sorna and Sarvani, Chodisetty and Margret, Jeffrey Justin and Mahalingam, Subathra and Amritkumar, Pavithra and Subramanyam, Paridhy Vanniya and S, Sarrath Rathnaraajan and Srisailapathy, C R Srikumari},
title = {Clinical Exome Sequencing Identifies, Two Homozygous LOXHD1 Variants in Two Inbred Families With Pre‐Lingual Hearing Loss From South India},
journal = {Annals of Human Genetics},
year = {2025},
doi = {10.1111/ahg.12593}
}
EUVIMED